Compare DDS & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDS | KRYS |
|---|---|---|
| Founded | 1938 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 10.3B |
| IPO Year | N/A | 2017 |
| Metric | DDS | KRYS |
|---|---|---|
| Price | $516.08 | $374.69 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $519.67 | $297.60 |
| AVG Volume (30 Days) | 95.5K | ★ 343.1K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.55% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $0.99 | $38.74 |
| Revenue Next Year | $1.09 | $32.53 |
| P/E Ratio | ★ $18.08 | $204.96 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $424.87 | $130.50 |
| 52 Week High | $741.98 | $382.54 |
| Indicator | DDS | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 73.60 |
| Support Level | $518.05 | $244.43 |
| Resistance Level | $593.14 | N/A |
| Average True Range (ATR) | 22.23 | 13.30 |
| MACD | -5.65 | 2.48 |
| Stochastic Oscillator | 3.38 | 88.14 |
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.